News

Q&A With RARE-X Disease Data Platform Founder, Nicole Boice

The nonprofit RARE-X is creating an easily-accessible, centralized data hub for all rare disease patient data that can help researchers answer questions about existing disorders, discover new ones, and work toward finding treatments. It was spun out of the work that Nicole Boice, founder and chief engagement officer of…

Rare Disease Day Events Bring Awareness, Equity to Patients

Since 2008, Rare Disease Day — the last day of February — has brought together patients, caregivers, family members, friends, and advocates from around the world to raise awareness and improve equity for the more than 7,000 known rare diseases that affect more than 300 million people. In 2022, the…

Changes in Gut Microbiota May Contribute to HAE Attacks

The richness and diversity of the gut’s microbial community, or microbiota, are significantly reduced in people with hereditary angioedema (HAE) who have had recent swelling attacks, when compared with that of healthy individuals, a single-center study in China shows. This difference was particularly pronounced among HAE patients with gastrointestinal…

Global Data Show Longer Delay in HAE Treatment for Patients in Spain

Spanish patients with hereditary angioedema reported fewer severe attacks and longer delays for treatment with Firazyr (icatibant injection) compared with patients from other countries, a retrospective analysis shows. Patients in Spain also reported longer‐lasting attacks. Overall, these findings from the Icatibant Outcome Survey highlight differences in disease management…

Antiviral Favipiravir Triggers Angioedema in Case Study of 2 Women

Favipiravir, an antiviral medication used to treat influenza and, more recently, COVID-19, may trigger angioedema in some individuals, a case study says. The report was published as a clinical commentary, titled “Angioedema After Favip[i]ravir Treatment: Two cases,” in the Journal of Cosmetic Dermatology. Angioedema, a condition characterized…